Trials / Completed
CompletedNCT03751761
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate safety and response rate of durvalumab/tremelimumab in combination with paclitaxel in patients with metastatic gastric cancers who fail a first-line chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | durvalumab, tremelimumab, paclitaxel | Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2) |
Timeline
- Start date
- 2018-06-11
- Primary completion
- 2023-08-30
- Completion
- 2023-08-30
- First posted
- 2018-11-23
- Last updated
- 2024-02-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03751761. Inclusion in this directory is not an endorsement.